DYAX 13.20 Dyax Corp $DYAX Hit a 52 week high of 13.50

New Post Public Reply Private Reply Replies (0) Message Board

Nov 14, 2014 at 11:49 AM

DYAX 13.20 Dyax Corp $DYAX Hit a 52 week high of 13.50 Closing the day 09:45 at 13.20 -0.14 -1.05% With a day low of 13.28 and a total volume of 41,988.

DYAX Recent Posts: http://investorshangout.com/Dyax-Corp-DYAX-53955/

DYAX Dyax Corp Recent Headline News

Dyax Up 73.8% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Mon Nov 10, 4:46PM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 6 months, Dyax has returned 73.76% as of today's recent price of $13.18.
DYAX: 12.94 (-0.40)

Why Dyax (DYAX) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:42AM CST
Dyax's stock not only has a decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well, suggesting that it could be a solid choice for investors.
DYAX: 12.94 (-0.40)

Can Dyax (DYAX) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:49AM CST
Dyax possess a positive long term growth rate and favorable Zacks Rank
DYAX: 12.94 (-0.40)

Dyax Shares Up 62.1% Since SmarTrend's Buy Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Nov 03, 10:56AM CST
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 62.07% as of today's recent price of $12.29.
DYAX: 12.94 (-0.40)

Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930
Business Wire - Mon Nov 03, 6:30AM CST
Dyax Corp. (NASDAQ: DYAX) today announced the expansion of its ongoing Phase 1b clinical trial evaluating DX-2930 to include additional patients and dosing cohorts. Dyax is developing DX-2930, an investigational fully human monoclonal antibody inhibitor of plasma kallikrein, as a subcutaneous injection for prevention of hereditary angioedema (HAE) attacks.
DYAX: 12.94 (-0.40)

BIND Therapeutics, Inc. (BIND) Surges: Stock Rises 14.2% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:11AM CDT
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 14% on the day.
BIIB: 304.20 (-13.78), AMAG: 34.48 (+0.24), BIND: 9.95 (+0.04), DYAX: 12.94 (-0.40)

Update: Biotech Dyax Exceeds Q3 Estimates With The Future Looking Bright
David Zanoni - at Seeking Alpha - Thu Oct 30, 11:15AM CDT

DYAX: 12.94 (-0.40)

Will Dyax (DYAX) Continue to Surge Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:04AM CDT
Will Dyax (DYAX) Continue to Surge Higher?
DYAX: 12.94 (-0.40)

Dyax ups earnings 87% in Q3
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 8:53AM CDT

DYAX: 12.94 (-0.40)

Dyax's (DYAX) CEO Gustav Christiansen on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 7:54PM CDT

DYAX: 12.94 (-0.40)

Dyax beats Street 3Q forecasts
Automated Insights - Tue Oct 28, 4:48PM CDT
BURLINGTON, Mass. (AP) _ Dyax Corp. (DYAX) on Tuesday reported a loss of $816,000 in its third quarter.
DYAX: 12.94 (-0.40)

Dyax (DYAX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Tue Oct 28, 3:55PM CDT

DYAX: 12.94 (-0.40)

Dyax beats by $0.05, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 3:16PM CDT

DYAX: 12.94 (-0.40)

Dyax Corp. Announces Third Quarter 2014 Financial Results
Business Wire - Tue Oct 28, 3:01PM CDT
Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2014. Dyax will host a webcast and conference call at 5:00 p.m. (ET) today to review financial results and provide updates regarding its key value drivers -including the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.94 (-0.40)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 4:35PM CDT

EA: 41.47 (+0.03), BXP: 127.40 (-0.44), AMP: 130.03 (unch), MRCY: 13.36 (-0.05), BLDP: 2.35 (-0.15), ESRX: 78.19 (+0.29), AJG: 47.94 (+0.02), NANO: 14.61 (+0.31), CAP: 22.26 (-0.10), EXTR: 3.68 (-0.01), HTA: 12.37 (-0.06), AEC: 19.71 (+0.16), MCK: 205.22 (+0.40), BGFV: 13.39 (+0.07), FB: 74.62 (+0.37), ARI: 16.49 (+0.04), EXP: 85.92 (+0.95), MWA: 9.68 (-0.05), DYAX: 12.94 (-0.40), FARO: 55.65 (+0.03), NFX: 32.90 (unch), KONA: 22.67 (-0.18), AZPN: 37.26 (+0.25), GILD: 102.12 (-2.08), HIW: 42.00 (-0.10), PEI: 22.24 (+0.11), GFIG: 4.85 (unch), CHRW: 73.76 (+0.65), HURN: 69.85 (+0.74), DLR: 68.88 (-0.18), HLIT: 6.79 (unch), AMCC: 5.95 (-0.14), INVN: 13.59 (-0.25), BOOM: 17.05 (+0.21), CINF: 51.36 (-0.01), KIM: 24.65 (-0.09), OI: 25.33 (-0.22), GPRE: 33.38 (+0.37), EPR: 56.55 (-0.18), APC: 89.02 (-0.44), IPHI: 13.64 (-0.34), HTS: 19.09 (+0.08), MAR: 78.16 (+0.07), INAP: 8.06 (+0.04), CRAY: 34.17 (+0.11), FEIC: 83.17 (+1.19), FISV: 70.50 (+0.13), DNB: 124.98 (-0.08), AFG: 60.36 (-0.02), CEB: 74.45 (+0.08), KEYW: 10.93 (+0.11), PLT: 51.57 (-0.03), MAC: 68.38 (+0.03), CHMT: 23.07 (-0.29), AFL: 59.07 (-0.07), CBT: 46.02 (-0.92), EIX: 62.08 (+0.40), EQR: 69.70 (-0.28)

Shares of DYAX Up 41.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Oct 27, 9:38AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 41.60% as of today's recent price of $10.74.
DYAX: 12.94 (-0.40)

Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon
PR Newswire - Mon Oct 27, 7:35AM CDT
Investor-Edge has initiated coverage on the following equities: Neurocrine Biosciences Inc. (NASDAQ: NBIX), Insmed Inc. (NASDAQ: INSM), BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Dyax Corporation (NASDAQ: DYAX), and Oncothyreon Inc. (NASDAQ: ONTY). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 24, 2014, the NASDAQ Composite ended at 4,483.72, up 0.69%, the Dow Jones Industrial Average advanced 0.76%, to finish the day at 16,805.41, and the S&P 500 closed at 1,964.58, up 0.71%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 754.42, up 1.38%, with the index also advancing 5.41% in the previous three months. Register for your complimentary reports on these five stocks at:
INSM: 13.65 (-0.10), BCRX: 10.08 (-0.31), NBIX: 18.88 (-0.26), ONTY: 1.63 (-0.05), DYAX: 12.94 (-0.40)

Dyax Has Returned 31.6% Since SmarTrend Recommendation (DYAX)
Comtex SmarTrend(R) - Mon Oct 20, 9:12AM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 31.58% as of today's recent price of $9.98.
DYAX: 12.94 (-0.40)

Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast
Business Wire - Tue Oct 14, 7:00AM CDT
Dyax Corp. (NASDAQ

YAX) will host a webcast and conference call, including an open question and answer session, Tuesday, October 28, 2014. During the call, management will discuss the Company's financial results for the third quarter 2014 as well as progress regarding its key value drivers - the KALBITOR(R) (ecallantide) business, DX-2930 and the Licensing and Funded Research Portfolio (LFRP).
DYAX: 12.94 (-0.40)

Dyax Up 25.6% Since SmarTrend Uptrend Call (DYAX)
Comtex SmarTrend(R) - Fri Oct 10, 5:12PM CDT
SmarTrend identified an Uptrend for Dyax (NASDAQ

YAX) on May 27th, 2014 at $7.59. In approximately 5 months, Dyax has returned 25.64% as of today's recent price of $9.53.
DYAX: 12.94 (-0.40)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Beetles Gel Polish Unveils Vibrant Fall Nail Carnival

Beetles Gel Polish Launches Fall Nail Carnival Here comes a new twist on fall fashion, and no, it ain’t your grandma's knitted sweater. We're talking nail polish—a vibrant, flashy ordeal brought to you by Beetles Gel Polish with their Fall Nail Carnival. They're rolling out this spectacle not just for your visions of grandeur nail ideas, but for those seeking deals...

WareSpace Expands Reach With $36.5M Acquisitions

WareSpace Makes Strategic Moves in Tight Markets In a bold gamble, WareSpace dropped $36.5 million to snag fresh industrial real estate in Miami Gardens, Florida, and South San Francisco, California. These aren't random picks, mind you. They're strategic grabs in markets where finding space ain't easier than winning the lottery. With more than 210 flexible units for small...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

American Savings Bank Surges 6% on NYSE Debut

American Savings Bank Lands with a Bang on NYSE Who would have thought American Savings Bank's (NYSE: ASBH) entry onto the stock market would start with such gusto? It's not every day you see a debut that impressive, with shares soaring 6.25% right out of the gate. Guess it's safe to say the folks over at ASBH did something right in the lead-up to their NYSE launch. CEO...

AI Coding Models' Self-Reporting Under Scrutiny with New Tool

Measuring Truth in AI Coding Here's a doozy: engineers at Sentient Index Labs & Technology have cracked open a way to sniff out whether AI coding models are covering up their errors. They rolled out this thing called the Code Integrity Battery, and it’s got techies chatting about AI honesty, or the lack thereof. It's not about AI writing shoddy code; that we can handle....

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Metriport Eyes Major Step in Health Data Integration

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Donatos Targets Texas: Pushing Franchise Growth Limits

Donatos Pizza: Ambitious Expansion in the Lone Star State When you think about pizza chains expanding, Donatos Pizza might not be the first name to come to mind, but they're cooking up something big in Texas. Folks in Dallas and Houston better be ready because Donatos is rolling out the red carpet for its edge-to-edge, topping-loaded pies all over Texas. Strategic Growth:...

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...